CKD-843 for male pattern baldness: a new treatment in Phase 3

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind study that compares two doses of CKD-843 to placebo and to dutasteride in men with androgenetic alopecia. Participants are assigned to one of four groups and followed for 12 months to measure hair growth and safety. The trial uses parallel groups and blinding to reduce bias. The lead sponsor is Chong Kun Dang Pharmaceutical, with the trial conducted at Seoul National University Hospital in Seoul, Korea.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Male of age 18-50 years
* Clinical Diagnosis of Androgenetic Alopecia
* Written informed consent

Key Exclusion Criteria:

* Other types of Alopecia or other diseases that can cause hair loss
* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
* Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose

Where it's running

• Seoul National University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: OhSang Kwon, MD, PhD — Seoul National University Hospital
• Study coordinator: OhSang Kwon, MD, PhD
• Email: oskwon@snu.ac.kr
• Phone: +2-2072-2417

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PP405 0.05% topically applied gel for adult men with pattern hair loss

  A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.

  Recruiting at 34 sites Phase 2/3 Pelage Pharmaceuticals, Inc. · Birmingham, Alabama and 62 other locations · NCT07819435

• EPI-001 for androgenetic alopecia in adults

  This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.

  Recruiting Phase 1/2 Epibiotech · Seoul, Seoul · NCT07618195

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• Secretome versus PRP injections to improve hair density in androgenetic alopecia

  This will try secretome injections versus platelet-rich plasma (PRP) injections to see which more effectively increases hair density and the terminal-to-vellus hair ratio in adults with androgenetic alopecia.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Denpasar, Bali · NCT07429253

• Fractional laser plus exosome vs. laser plus placebo for androgenetic alopecia

  This study tests whether adding a human umbilical cord mesenchymal stem cell exosome solution to fractional laser therapy helps men with androgenetic alopecia grow more hair than laser therapy with a placebo.

  Recruiting Chang Gung Memorial Hospital · Taoyuan, Taoyuan · NCT07248410

• Once-daily 5% minoxidil foam for female pattern hair loss

  This will try once-daily 5% minoxidil foam to see if it increases hair count in adult women with androgenetic alopecia compared with a placebo.

  Recruiting Phase 3 Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Beijing · NCT07080931

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.